Moura Alexandra, Leclercq Alexandre, Vales Guillaume, Tessaud-Rita Nathalie, Bracq-Dieye Hélène, Thouvenot Pierre, Madec Yoann, Charlier Caroline, Lecuit Marc
Institut Pasteur, National Reference Centre and WHO Collaborating Centre Listeria, 75015, Paris, France.
Institut Pasteur, Université Paris Cité, Inserm U1117, Biology of Infection Unit, 75015, Paris, France.
Lancet Reg Health Eur. 2023 Dec 14;37:100800. doi: 10.1016/j.lanepe.2023.100800. eCollection 2024 Feb.
Large-scale studies are needed to clarify antimicrobial resistance in the foodborne pathogen () and the effectiveness of listeriosis treatment options. Here we examined the antimicrobial resistance patterns in over time and assessed genotype-phenotype concordances.
We analyzed 5339 isolates (2908 clinical and 2431 food isolates) collected in France and overseas territories, between 2012 and 2019. Whole genome sequencing was performed for all isolates and antimicrobial resistance profiles inferred from draft assemblies. Antimicrobial susceptibility towards 22 antimicrobials was determined for all clinical isolates, and in food isolates with acquired resistance genes.
All tested isolates were resistant to at least 3 different classes of antimicrobials, consistent with intrinsic traits. Acquired antimicrobial resistance in was rare (2.23% isolates) and more prevalent in food (mainly lineage II) compared to clinical isolates (mainly lineage I) (3.74% vs 0.98%, < 0.0001), and in isolates with disinfectants or stress resistance traits (e.g. 20.20% vs 7.20%, < 0.0001), suggesting co-selection of resistance in food-production environments. Acquired antimicrobial resistance could be predicted from genomes with high accuracy (>99%), except for ciprofloxacin. Acquired antimicrobial phenotypes were towards tetracyclines (mostly due to ), trimethoprim (), lincosamides (), macrolides (, ) and phenicols ().
The reference treatment for listeriosis (aminopenicillins/aminoglycosides) remains effective, with no acquired resistance observed. Continuous surveillance of antimicrobial resistance in clinical and food isolates is crucial to detect the emergence of novel resistance.
Institut Pasteur, INSERM, Santé Publique France, Investissement d'Avenir program Laboratoire d'Excellence 'Integrative Biology of Emerging Infectious Diseases' (ANR-10-LABX-62-IBEID).
需要开展大规模研究以阐明食源性病原体()的抗菌药物耐药性以及李斯特菌病治疗方案的有效性。在此,我们研究了一段时间内的抗菌药物耐药模式,并评估了基因型与表型的一致性。
我们分析了2012年至2019年间在法国及海外领地收集的5339株分离株(2908株临床分离株和2431株食品分离株)。对所有分离株进行了全基因组测序,并从草图组装中推断出抗菌药物耐药谱。测定了所有临床分离株以及带有获得性耐药基因的食品分离株对22种抗菌药物的敏感性。
所有测试分离株均对至少3种不同类别的抗菌药物耐药,这与的固有特性一致。获得性抗菌药物耐药性在中较为罕见(2.23%的分离株),与临床分离株(主要是谱系I)相比,在食品分离株(主要是谱系II)中更为普遍(3.74%对0.98%,<0.0001),在具有消毒剂或应激抗性特征的分离株中也是如此(例如20.20%对7.20%,<0.0001),这表明在食品生产环境中存在耐药性的共同选择。除环丙沙星外,获得性抗菌药物耐药性可通过基因组以高精度(>99%)预测。获得性抗菌药物表型针对四环素类(主要由于)、甲氧苄啶()、林可酰胺类()、大环内酯类(,)和氯霉素类()。
李斯特菌病的参考治疗方法(氨基青霉素/氨基糖苷类)仍然有效,未观察到获得性耐药。持续监测临床和食品分离株中的抗菌药物耐药性对于检测新出现的耐药性至关重要。
巴斯德研究所、法国国家健康与医学研究院、法国公共卫生署、未来投资计划卓越实验室“新兴传染病综合生物学”(ANR-10-LABX-62-IBEID)。